Huang et al. (2020) stated the anticancer activity of EGCG against endometrial, breast, and ovarian cancers via Nrf2 activation, NF‐κB downregulation, and interaction with DNMTs and histone deacetylases (HDACs). This evidence concerns the gene NFKB1 and ovarian cancer.